Details of the Drug Pharmacogenomic Perturbation Atlas

Topotecan Drug Info

Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

60700

ChEBI ID

CHEMBL63632

CAS Number

CAS 123948-87-8

TTD Drug ID

D02PMO

VARIDT Drug ID

DR00044

ACDINA Drug ID

D00690

General Information of Drug (ID: DMP6G8T)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.43	0.00e+0	63/73 (86.3%)	SESN1;CDKN1A;DDB2;...
Graft-versus-host disease	2.29	0.00e+0	32/42 (76.19%)	HLA-B;FAS;HLA-DQA1;...
Type I diabetes mellitus	2.25	0.00e+0	38/43 (88.37%)	HLA-B;FAS;HLA-DQA1;...
Epstein-Barr virus infection	2.18	0.00e+0	189/202 (93.56%)	CDKN1A;DDB2;HLA-B;...
Allograft rejection	2.15	0.00e+0	32/38 (84.21%)	HLA-B;FAS;HLA-DQA1;...
Herpes simplex virus 1 infection	2.09	0.00e+0	165/498 (33.13%)	HLA-B;FAS;TAP1;...
Autoimmune thyroid disease	2.07	0.00e+0	46/53 (86.79%)	HLA-B;FAS;HLA-DQA1;...
Antigen processing and presentation	1.97	1.08e-3	60/78 (76.92%)	HLA-B;TAP1;HLA-DQA1;...
Staphylococcus aureus infection	1.96	1.92e-3	72/95 (75.79%)	KRT17;KRT18;KRT14;...
Viral myocarditis	1.91	2.60e-3	53/60 (88.33%)	CXADR;HLA-B;HLA-DQA1;...
Influenza A	1.89	3.15e-3	156/172 (90.7%)	FAS;HLA-DQA1;TNFRSF10B;...
Lysosome	1.86	3.61e-3	115/128 (89.84%)	FUCA1;GAA;AP1S2;...
Viral protein interaction with cytokine and cytokine re...	1.86	3.33e-3	84/100 (84%)	TNFRSF10B;CXCL13;CXCL14;...
Other glycan degradation	1.86	3.09e-3	13/18 (72.22%)	FUCA1;MAN2B1;HEXA;...
Inflammatory bowel disease	1.79	6.93e-3	58/65 (89.23%)	HLA-DQA1;MAF;IL1B;...
Glycosaminoglycan degradation	1.77	8.66e-3	19/19 (100%)	HEXA;IDS;HEXB;...
Measles	1.76	8.66e-3	133/139 (95.68%)	FAS;CASP8;MX2;...
Cytosolic DNA-sensing pathway	1.72	1.49e-2	52/63 (82.54%)	POLR2H;IRF7;IL1B;...
Toll-like receptor signaling pathway	1.72	1.41e-2	94/104 (90.38%)	CASP8;CXCL8;LY96;...
Thyroid cancer	1.69	1.95e-2	36/37 (97.3%)	CDKN1A;DDB2;GADD45A;...
NF-kappa B signaling pathway	1.69	1.86e-2	90/104 (86.54%)	GADD45A;CXCL8;BCL2L1;...
Small cell lung cancer	1.67	2.09e-2	90/92 (97.83%)	CDKN1A;DDB2;GADD45A;...
Apoptosis	1.67	2.18e-2	126/168 (75%)	PMAIP1;FAS;GADD45A;...
RIG-I-like receptor signaling pathway	1.66	2.27e-2	64/70 (91.43%)	ISG15;CASP8;CXCL8;...
Pertussis	1.64	2.46e-2	64/76 (84.21%)	CXCL8;LY96;ITGAM;...
Hepatitis C	1.63	2.50e-2	139/157 (88.54%)	CDKN1A;FAS;CASP8;...
Oxidative phosphorylation	1.63	2.57e-2	93/133 (69.92%)	NDUFB1;NDUFS3;ATP6AP1;...
Taurine and hypotaurine metabolism	1.63	2.47e-2	8/11 (72.73%)	ADO;CSAD;GGT1
Leishmaniasis	1.62	2.87e-2	67/77 (87.01%)	HLA-DQA1;PTGS2;NCF2;...
Human immunodeficiency virus 1 infection	1.59	3.63e-2	189/212 (89.15%)	HLA-B;FAS;TAP1;...
Long-term depression	-1.62	4.83e-2	55/60 (91.67%)	PRKG1;GUCY1B1;GNA13;...
Cholinergic synapse	-1.63	4.79e-2	99/113 (87.61%)	BCL2;ADCY1;KRAS;...
Steroid biosynthesis	-1.63	4.81e-2	19/20 (95%)	NSDHL;CYP51A1;FDFT1;...
mTOR signaling pathway	-1.64	4.49e-2	114/154 (74.03%)	DDIT4;FZD7;ATP6V1H;...
Aldosterone synthesis and secretion	-1.65	4.66e-2	85/98 (86.73%)	ATP1B3;ATP1B1;CYP11A1;...
Gastric acid secretion	-1.65	4.92e-2	63/76 (82.89%)	ADCY1;ATP1A1;KCNK2;...
Protein processing in endoplasmic reticulum	-1.65	4.68e-2	127/171 (74.27%)	SSR2;HYOU1;ATXN3;...
Pancreatic secretion	-1.66	4.91e-2	87/102 (85.29%)	ITPR3;ATP2A3;PLA2G5;...
GnRH signaling pathway	-1.67	3.81e-2	80/93 (86.02%)	RAF1;ADCY1;SOS2;...
Dopaminergic synapse	-1.67	4.09e-2	115/132 (87.12%)	KIF5C;MAPK9;MAPK10;...
Regulation of actin cytoskeleton	-1.68	4.31e-2	185/218 (84.86%)	CXCL12;ITGA1;LPAR4;...
Axon guidance	-1.69	4.02e-2	151/182 (82.97%)	RGS3;ARHGEF12;GNAI3;...
Cushing syndrome	-1.70	3.77e-2	125/155 (80.65%)	BRAF;CACNA1D;RAP1B;...
Rap1 signaling pathway	-1.70	4.15e-2	184/210 (87.62%)	BRAF;RAPGEF4;RAP1GAP;...
Progesterone-mediated oocyte maturation	-1.77	2.49e-2	75/100 (75%)	CDC25A;PDE3B;ANAPC1;...
Wnt signaling pathway	-1.80	1.40e-2	124/166 (74.7%)	FZD4;RAC3;APC;...
Gap junction	-1.80	1.60e-2	72/88 (81.82%)	RAF1;ADCY1;SOS2;...
Sphingolipid signaling pathway	-1.82	1.31e-2	106/119 (89.08%)	SGMS1;CERS6;PPP2R3A;...
Cortisol synthesis and secretion	-1.82	1.57e-2	58/65 (89.23%)	ADCY1;KCNK3;KCNK2;...
Melanogenesis	-1.91	0.00e+0	74/101 (73.27%)	FZD4;GNAI3;RAF1;...
Oocyte meiosis	-1.94	0.00e+0	90/129 (69.77%)	FBXO5;MAD2L1;CDC25C;...
Long-term potentiation	-2.06	0.00e+0	61/67 (91.04%)	PPP1CC;RAF1;ADCY1;...
Adherens junction	-2.07	0.00e+0	63/71 (88.73%)	FGFR1;NLK;MAP3K7;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.04uM - 10uM	6H, 24H

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H

NL20	CVCL_0461	Homo sapiens	10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	24H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HFL1	CVCL_4295	Homo sapiens	10uM	24H

IMR-90	CVCL_0347	Homo sapiens	10uM	24H

WI-38	CVCL_0579	Homo sapiens	10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H